Further health economics data validates Creo technology

Savings of over £10,000 per procedure using Speedboat Inject instead of traditional surgery

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that data from the paper titled: ‘Cost-effectiveness analysis of Speedboat submucosal dissection in the management of large non-pedunculated colorectal polyps’ demonstrates that the use of Speedboat Inject is highly likely to be a cost-effective strategy for treating both benign and malignant large non-pedunculated colorectal polyps1 (“LNPCP”) and can lead to cost savings in NHS Hospitals of over £10,000 per procedure versus a traditional surgical outcome for patients, a saving of approximately 50 per cent. This is double the saving of that which was first suggested and announced by Creo in June 2020.

Clinical data confirms that the health economic benefits through using the Company’s CROMA Advanced Energy Platform with Speedboat Inject provides substantially more cost-savings for the NHS than originally thought. This prospective database analysis of 50 patients with LNPCP analysed costs that were valued from the NHS and Personal Social Service. The study concluded that the substantial cost-savings were driven by reducing downstream costs associated with recurrences of lesions, combined with procedure-related complications.

Endoscopists, using traditional techniques to perform a procedure, would ordinarily see a patient have 30cm of bowel removed surgically, under general anaesthetic, with the associated risks and costs of up to five days in hospital. However, using Creo’s Speedboat Inject device enables the removal of gastrointestinal pre-cancerous lesions under sedation, with patients generally able to leave hospital on the same day that the procedure is performed.

Craig Gulliford, Chief Executive Officer of Creo, commented:

We are extremely pleased to see this health economics data providing evidence that our Speedboat procedure could save the NHS over £10,000 per procedure. Our passion has always been to improve patient outcomes, not only through developing innovate medical devices to bring advanced energy to endoscopy, but to also offer economic benefits to healthcare providers, in turn allowing their limited resources to be applied elsewhere; this data demonstrates that. Following the commercial agreement we signed with the Department of Health and Social Care in 2020, offering health service bodies access to our devices at preferential rates, we continue our efforts to train more surgeons to use our technology, allowing the patients and NHS to benefit.

Posted 05/26/21

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment